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INTRODUCTION 
Acute Ischemic Stroke is one of the leading causes of death and 
disability in developed nations and is increasing rapidly in the developing 
world.  The prevalence of cerebrovascular disease has progressively increased 
in India during the last half century.  Therefore, an aggressive outlook for the 
evaluation of cerebrovascular disease is required for some special risk factors 
apart from the conventional risk factors. 
         Antiphospholipid antibodies are a heterogenous family of autoantibodies 
that are directed against the negatively charged phospholipids such as 
cardiolipin, phosphatidyl serine, phophatidyl inositol. 
         The antiphospholipid antibodies, which are directed against cardiolipin, 
have been associated with accelerated atherosclerosis, which is the 
pathophysiological basis for an ischemic stroke.  They have been implicated as 
one of the most common acquired protein defects causing thrombosis1. 
         The binding of antibodies to cardiolipin requires a cofactor.  The β2 
glycoprotein also known as apolipoprotein H is a highly glycosylated plasma 
protein that appears to be the major, but not the only cofactor for the 
recognition of cardiolipin.  Other Cofactors are prothrombin, Protein C, Protein 
S and  thrombomodulin.  The presence of β2GP1 dependent antibodies was 
shown to be more specific for thrombosis than non-β2 GP1 dependent 
anticardioloipin antibodies. 
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         Due to the unexplained aetiology in large number of young stroke 
patients and absence of conventional predisposing risk factors like HT, DM, 
Dyslipidemia the importance of antiphospholipid antibodies increased many 
fold. 
         In India, a few studies have been conducted regarding the prevalence of 
anti cardiolipin antibodies. 
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AIM OF THE STUDY 
1. To find out the prevalence of β2 – Glycoprotein 1 Dependent 
Anticardiolipin Antibodies (β2 GP1) of isotype IgG and IgM in 
patients with acute ischemic stroke who were 55 years old (or) 
younger.  
2. To find out the correlation between the conventional 
cerebrovascular risk factors and the anticardiolipin antibodies. 
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REVIEW OF LITERATURE 
         Among all the neurological diseases of adult life, the cerebrovascular 
ones clearly rank first in frequency and importance.  After the heart disease and 
cancer, it is the third most common cause of death in the United States.  In the 
last decade, according to the American Heart Association, the total number of 
strokes may again be rising2.     
THE CAUSES OF CEREBRAL ISCHEMIA AND INFARCTION  
Arterial wall disorders 
¾ Atherothromboembolism 
¾ Intracranial small vessel disease (lipophyalinosis, arteriolosclerosis, 
microatheroma) 
¾ Trauma 
¾ Dissection 
¾ Fibromuscular dysplasia 
¾ Congenital arterial anomalies 
¾ Moyamoya syndrome 
¾ Embolism from arterial aneurysms 
¾ Inflammatory vascular diseases 
¾ Irradiation 
¾ Infections 
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Embolism from the heart 
Haematological disorders 
Miscellaneous conditions 
¾ Pregnancy/puerperium 
¾ Oral contraceptives and other female sex hormones 
¾ Drug abuse 
¾ Cancer 
¾ Perioperative 
¾ Migraine 
¾ Inflammatory bowel disease 
¾ Homocystinaemia 
¾ Fabry’s disease 
¾ Mitochondrial cytopathy 
¾ Hypoglycaemia 
¾ Fibrocartilaginous embolism 
¾ Snake bite 
¾ Fat embolism 
¾ Epidermal naevus syndrome 
¾ Nephrotic syndrome 
¾ CADASIL 
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  Most cerebrovascular diseases can be attributed to atherosclerosis.  It is 
more likely to occur in patients with certain risk factors for this disease.  
Despite the fact that most cerebrovascular events are explained by the 
conventional risk factors, the search for additional etiologic agents continues.  
In recent years a number of new candidate risk factors (or) markers have been 
proposed as significant predictors of atherosclerosis and its complications. 
MAJOR INDEPENDENT RISK FACTORS 
• Advancing age 
• Tobacco smoking 
• Diabetes Mellitus 
• Elevated total and low-density lipoprotein 
• Hypertension 
PREDISPOSING RISK FACTORS 
• Abdominal obesity 
• Ethnic atherosclerosis 
• Family history of premature coronary heart disease 
• Obesity 
• Physical inactivity 
• Psychosocial factors 
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NOVEL RISK FACTORS FOR ATHEROSCLEROTIC VASCULAR 
DISEASE3 
1. Inflammatory markers 
• C-reactive protein 
• Interleukins (eg. IL-6) 
• Serum Amyloid A 
• Vascular and cell adhesion molecules 
• Soluble CD 40 ligand 
• Leukocyte count 
• Hemostasis / Thrombosis markers 
• Fibrinogen 
• Von willebrand factor antigen 
• Plasminogen activator inhibitor 1 (PAI-1) 
• Tissue plasminogen activator 
• D-dimer 
• Fibrinopeptide A 
• Prothrombin fragment  
• Platelet related factors 
• Platelet aggregation 
• Platelet activity 
• Platelet size and volume 
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2. Lipid-related factors 
• Small dense low-density lipoprotein 
• Lipoprotein (a) 
• Remnant lipoproteins 
• Apolipoproteins A1 and B 
• High-density lipoprotein subtypes 
• Oxidized LDL 
3.  Other factors 
• Homocysteine 
• Lipoprotein-associated phospholipase A(2) 
• Micro albuminuria 
• Insulin resistance 
• PAI-1 genotype 
• Angiotensin-converting enzyme genotype 
• ApoE genotype 
• Infectious agents – cytomegalaovirus, Chlamydia pneumonia, 
Helicobacter pylori, Herpes simplex virus 
ATHEROTHROMBOEMBOLISM AND CEREBRAL ISCHEMIA 4 
         Atheroma seems to be an almost inevitable accompaniment of ageing, at 
least in developed countries.  It is by far the most common arterial disorder 
and, when complicated by thrombosis or embolism, is the most frequent, but by 
no means only, cause of cerebral ischaemia and infarction. 
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The approximate relative frequency of the main causes of ischaemic stroke 
and TIA 
Atherothrombosis affecting large and medium-sized arteries 
between the heart and the brain 
50% 
Intracranial small vessel disease (small vessel disease 
lipophyalinosis / microatheroma, etc.) 
25% 
Embolism from the heart 20% 
Miscellaneous rare disorders 5% 
 
Distribution of atheroma 
         Atheroma mainly affects large (e.g. aortic arch) and medium sized 
arteries at places of arterial branching (e.g. carotid bifurcation), tortuosity (e.g. 
carotid siphon), and confluence (e.g.basilar artery).  These are sites of 
haemodynamic sheer stress and thus endothelial trauma; boundary layer 
separation, blood stagnation, and the accumulation of platelets; and of 
turbulence, all of which are likely to promote thrombosis.  This might explain 
the distribution of atheroma in the cerebral circulation if thrombosis is 
intimately involved with its progression, even if not in its very beginnings.  It is 
remarkable how free of atheroma some sites can be: for example, the internal 
carotid artery (ICA) between the commonly affected origin and less commonly 
affected siphon, and the main cerebral arteries distal to the circle of Willis.  
However, in the same individual, atheroma in one place does tend to be 
accompanied by atheroma in other parts of the same artery, with atheroma in 
other arteries to the brain, and in arteries to other organs such as the heart.  
Presumably this reflects individual susceptibility to atheroma as a result of the 
presence of causal vascular risk factors (such as hypertension) and genetic 
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predisposition which determines who will develop atheroma, while the arterial 
anatomy determines where the lesions occur.  None the less, it is curious how 
severely one arterial site can be affected and yet, in the same individual, the 
mirror-image site on the other side of the body is still normal, perhaps because 
of subtle asymmetries in arterial geometry. 
Natural history of atheroma 
         Atheroma starts in childhood, it is thought in response to endothelial 
injury.  Intimal fatty streaks appear first.  In a gradual process stretching over 
many years, circulating monocyte-derived macrophages adhere to and invade 
the arterial wall, there is an inflammatory response with cytokine production 
and T-lymphocyte activation, intra and later extracellular cholesterol and other 
lipids are deposited, particularly in macrophages which are then described as 
foam cells, smooth muscle cells proliferate, fibrosis occurs, and so fibrolipid 
plaques are formed.  Necrosis and calcification complicate advanced lesions.  
These atheromatous plaques invade the media, gradually spread around and 
along the arterial wall and narrow the lumen, although at times the vessel 
dilates.  The plaques are complicated by platelet adhesion, activation, and 
aggregation, which initiates blood coagulation and subsequent thrombosis. 
         Thrombus may be incorporated in to the atheromatous plaques which 
then re-endothelialize; it may grow to obstruct the arterial lumen and then 
propagate proximally or distally in the stagnant column of blood as far as the 
next branching point or beyond; it may be lysed by natural fibrinolytic 
mechanisms in the vessel wall; or it may embolize in whole or in part to 
occlude a distal artery, usually at a branching point.  Such artery-to-artery 
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emboli vary in size and shape, and consist of some combination of cholesterol 
debris from the atheromatous plaque, platelet aggregates, and fibrin, which 
may be newly formed and relatively friable, or old and well organized. 
Depending on local blood flow and on the size, composition, and consistency 
of the impacted emboli, they may be lysed, fragment, and vanish into the 
microcirculation, or remain to occlude the artery and promote local thrombosis.  
Thrombosis is further encouraged by the release from platelets of thromboxane 
A2, which is also a vasoconstrictor.  However, it is opposed by prostacyclin and 
nitric oxide, both vasodilators, released from vascular endothelium, as well as 
by endothelium derived plasminogen activator.  The balance of pro and 
antithrombotic factors determines whether a thrombus complicating an 
atheromatous plaque or an occlusive embolus, grows, is lysed, or is 
incorporated into the vessel wall. 
         It is likely that atheromatous plaques become ‘active’ or ‘unstable’ from 
time to time as a result of fissuring and cracking of thin parts of the fibrous cap 
which covers the rather rigid lesion; of ulceration perhaps; or sometimes of 
haemorrhage within the plaque, rather than the more commonly found 
haemorrhage entering via a crack in the endothelial surface.  Any of these 
events exposes the highly thrombogenic necrotic core of the plaque to blood 
and so causes thrombus to form and then perhaps to embolize.  Thus, 
atherothromboembolism can be regarded as an acute on chronic disease; at any 
one time a plaque may be static and quiescent with a thick fibrous cap, slowly 
growing but asymptomatic, or active with ongoing thrombosis and 
embolization, which may or may not be symptomatic depending on the depth 
and duration of the consequent ischaemia.  This concept may explain the 
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tendency for TIAs to cluster, for stroke to occur early after a TIA and to affect 
the same arterial territory, for presumed artery-to-artery embolic strokes to 
recur early, and for the risk of stroke to decline with time even distal to a 
severe symptomatic stenosis. 
         Complicated atheromatous lesions which eventually become fibrotic and 
heavily calcified make the whole artery rigid, elongated and so tortuous, and 
sometimes ectatic.  Ectasia and aneurysmal bulging, particularly of the basilar 
artery, may compress adjacent structures, such as the lower cranial nerves and 
brainstem.  Also, emboli may be released from the atheromatous walls and 
complicating thrombosis.  However, arterial rupture is exceptional. 
         Atherothrombotic plaques are clearly highly dynamic lesions, progressing 
and regressing in various parts of the arterial tree at different rates and at 
different times, usually showing layers of thrombus of different ages.  
Progression and regression of these atherothrombotic lesions can, to some 
extent, be followed non invasively in humans with ultrasound imaging, but is 
difficult to distinguish atheroma, which is likely to change only slowly, from 
thrombus, which may grow or be lysed much faster.  Also, intraplaque 
haemorrhage presumably may cause quite sudden enlargement of a plaque, 
followed by fairly rapid shrinkage as the haematoma is absorbed.  Recently it 
has become possible to monitor the release of emboli from carotid plaques, and 
elsewhere, into the cerebral circulation with transcranial Doppler of the middle 
cerebral artery, again an indication of plaque ‘instability’.  Not surprisingly, 
high intensity embolic signals are more common distal to symptomatic 
compared with asymptomatic stenosis, but even then the number is rather low, 
perhaps because of technical difficulties or insufficient recording time. 
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         Symptoms of focal ischaemia occur as a consequence of reduced blood 
flow which, in the context of aatheroma, is most commonly due to embolism 
from a plaque complicated by thrombosis in an extracranial artery (such as the 
carotid bifurcation) to occlude a smaller intracranial artery (such as the 
mainstem or branch of the middle cerebral artery (MCA)).  The notion that the 
carotid siphon might filter out emboli en route to the brain is interesting but 
unproven. Occasionally emboli may reach the brain via the collateral 
circulation; for example from a stenosed internal carotid artery (ICA) across 
the circle of Willis into the MCA distal to an occluded contralateral ICA; from 
thrombus in the blind proximal stump of an occluded contralateral ICA, a 
stenosed proximal external carotid artery (ECA) or from more proximal sites of 
atheroma, but all via the ECA and through the ophthalmic circulation to the 
carotid siphon and beyond.  Also, emboli may arise from the distal end of a 
thrombus occluding the ICA.  Finally, ischaemia may occur due to 
haemodynamic compromise beyond an occluded ICA.  Furthermore, focal 
ischaemia may occur between arterial territories (i.e. in boundary zones) 
usually due to low flow distal to an occluded artery. 
         Symptomatic in situ atherothrombotic occlusion does not appear to be 
very common in the anterior cerebral circulation, perhaps because the most 
commonly affected site for atheroma is in a relatively large artery (i.e. the ICA 
origin) rather than in smaller arteries, such as the MCA, which are more often 
occluded by embolism than by in situ atherothrombosis.  Another reason might 
be the relatively effective collateral circulation distal to any occlusion in the 
extracranial carotid system.  On the other hand, symptomatic atherothrombotic 
occlusion does appear to be more common in the posterior circulation, 
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particularly in the basilar artery.  But even here, embolism from non-occlusive 
thrombus in to smaller arteries supplying the brainstem and elsewhere is well 
described. 
         In an individual patient it is relatively easy to diagnose acute focal 
ischaemia or infarction but, because angiography is seldom done early, or at 
all, it is difficult to know what the pattern of any arterial pathology is and 
exactly how the ischaemia has occurred.  Even when angiography, or 
(increasingly often) ultrasound of the extra and intracranial circulation, reveals 
an occluded artery, this does not necessarily mean that the occlusion was 
recent, or that it was embolic rather than due to in situ thrombosis, or whether 
any embolism had occurred via collaterals or from the distal end of the 
occluded thrombus, or whether the ischaemia was due to low flow distal to an 
old occlusion.  So, it is now clear that occluded arteries can recanalize 
spontaneously quite quickly, particularly the mainstem of the MCA.  Possibly 
emboli from the heart are more likely to lyse than those from atheromatous 
arteries, and thrombotic occlusion of the MCA or ICA is perhaps less likely to 
open spontaneously.  Recanalisation rates presumably also depend on the 
constituents and age of the occluding material.  However, whatever the exact 
cause of the ischaemia, any demonstrated arterial pathology in the aorta, neck, 
basilar artery, or circle of Willis is usually atherothrombosis and the 
assumption is then reasonably made that thromboembolism has occurred at 
some stage and is likely to occur again.  If, as is so often the case, little or no 
arterial pathology is demonstrated by vascular imaging, or macroscopically at 
postmortem, then focal ischaemia is most likely due to embolism from the 
heart or to intracranial small vessel disease.   
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American Heart Association Classification (1995) of  
Human  Atherosclerosis 
 
Types Main Histology Main Pathogenesis Age Tonset Clinical 
Type I : 
Initial lesions 
Macrophages, 
occasional foam 
cell 
Accumulation 
of liporotein 
Ist decade Asympotomatic 
Type II : 
Fatty streaks 
Many layers of 
macrophages and 
foam cells 
Accumulation 
of liporotein 
Ist decade Asymptomatic 
Type III : 
Intermediate 
lesions 
Many lipid-laden 
cells and scattered 
extracellular lipid 
droplets 
Accumulation 
of liporotein 
3rd decade Asymptomatic 
Type IV : 
Atheromatous 
lesions 
Intra-as well as 
extra-cellular lipid 
pool 
Accumulation 
of liporotein 
3rd decade Asymptomatic 
or manifest 
symptoms 
Type V : 
Fibrofatty 
lesions 
Fibrotic cap and 
lipid core (Va), 
may have 
calcification (V b) 
Smooth muscle 
cell 
proliferation 
and increased 
collagen 
4th decade Asymptomatic 
or manifest 
symptoms 
Type VI : 
Complicated 
lesions 
Ulceration, 
haemorrhage, 
haematoma, 
thrombosis 
Haemodynamic 
stress, 
thrombosis, 
haematoma 
4th decade Asymptomatic 
or manifest 
symptoms 
 
Atherosclerosis is a complex and indolent histopathological process, 
which is considered to be the most common underlying process in 
cerebrovascular disease.  In recent years it has become apparent that in addition 
to the traditional risk factors for atherosclerosis, this condition is associated 
with infectious, inflammatory and autoimmune factors5.  Atherosclerosis 
fulfills all the four criteria delineated by Witebsky and Rose to define a 
condition as autoimmune in nature and all arms of the immune system 
(including cellular components, auto antigens and auto antibodies) play a part 
in atherosclerosis.6 
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INVOLVEMENT OF CELLULAR COMPONENTS IN 
ATHEROSCLEROSIS 
         There is good evidence to suggest that cellular components of the 
immune system are involved in atherosclerosis.  Studies using transgenic 
murine models show recruitment of mononuclear leucocytes through vascular 
leucocyte adhesion molecules and chemokines, differentiation of monocytes to 
macrophages, and endocytosis through scavenger receptors of oxidized low-
density lipoprotein in atherogenesis.  The importance of T cells in 
atherosclerosis is emphasized in a study in which CD4+ and CD8+ T cell 
depletion reduced fatty streak formation in C57BL/6 mice, indicating that T 
cells aggravate fatty streak formation.7  A recent study emphasizes also the 
importance of specific lymphocytes.  Lymphocytes obtained from low-density 
lipoprotein receptor deficient mice immunized with β2 glycoprotein were 
transferred intraperitoneally into syngenic mice, producing larger fatty streaks 
in the recipients than in mice receiving lymphocytes from the control mice.8 T 
cell depletion of lymphocytes failed to induce this effect.  Hence, β2 
glycoprotein reactive T cells could promote atherogenesis. 
         It is also of interest to determine whether atherosclerosis is mainly a T 
helper 1 or T helper 2 mediated conditions.  Although it is not yet sufficiently 
clear, a recent study favors the former. 
ASSOCIATION BETWEEN AUTOANTIBODIES AND 
ATHEROSCLEROSIS 
         Apart from the involvement of cellular components in atherosclerosis, the 
evidence also suggests an association between autoantibodies and 
atherosclerosis (reviewed by Shoenfeld et al9). The major antigenic targets for 
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auto antibodies during atherogenesis are the oxidized lipids such as the 
oxidized low-density lipoprotein, heat shock proteins (hsp) 60/65, and 
phospholipids such as cardiolipin10, 11, 12 
Anti-oxidized low-density lipoprotein antibodies 
         Oxidation of low-density lipoprotein probably has an important role in 
the pathogenesis of atherosclerosis.  It is not yet firmly established whether the 
immune response to oxidized low-density lipoprotein is pro-atherogenic or anti 
atherogenic in vivo, or alternatively, whether an epiphenomenona for the 
presence of oxidized low-density lipoprotein.  Anti-oxidized low-density 
lipoprotein antibodies are raised in patients with early onset peripheral vascular 
disease, severe carotid atherosclerosis,13 and angiographically verified coronary 
artery disease.14, 15 
Anti-heat shock protein (HSP) 60/65 antibodies 
         Heat shock proteins are a family of proteins that shows a highly 
homologous sequence between different species from bacteria to man.  
Sonographic assessment of carotid atherosclerotic lesions showed that subjects 
with such lesions had significantly raised levels of anti-heat shock protein 65 
antibodies compared with controls.16 Early atherosclerosis was significantly 
enhanced in mice fed high cholesterol that was immunized with heat shock 
protein 65.  Recently it has been suggested that IL4 has a crucial role in the 
progression of early atherosclerosis mediated by inflammation, as IL4 
knockout mice immunized with heat shock protein 65 had significantly less 
fatty streak formation that lesions in C57BL/6 mice.17 
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ANTINUCLEAR ANTIBODIES IN ATHEROSCLEROSIS 
         Grainger and Bethel provided evidence for the presence of antinuclear 
antibodies in patients with radiological evidence of advanced atherosclerosis.  
Their discussion includes the possibility that these antibodies are merely an 
epiphenomenona or, alternatively, that they have a pathogenic role in 
ahterosclerosis.18 Even though this study naturally does not provide answers to 
that crucial question, their finding itself is important and raises several thoughts 
and assumptions. 
         The accelerated atherosclerotic state found in patients with systemic lupus 
erythematosus and antiphospholipid syndrome might result from the higher 
frequency of traditional risk factors in these patients as well as the presence of 
anticardiolipin and anti-β2glycoprotein1 antibodies.19 However, antinuclear 
aantibodies might also contribute to the accelerated atherosclerosis found in 
these patients.  Further, the association of antinuclear antibodies with 
atherosclerosis raises the possibility that these antibodies play a part in 
atherogenesis of arteriosclerosis in other autoimmune and inflammatory states, 
such as vasculitis.  As for other antibodies, the frequency of antinuclear 
antibodies is significantly higher in the elderly people (10 – 37%) than in the 
young (0 – 6%).20   
ANTIPHOSPHOLIPID ANTIBODIES IN ATHEROSCLEROSIS 
         Anticardiolipin antibodies have been associated with accelerated  
atherosclerosis. They are a heterogenous family of auto antibodies that are 
directed against the negatively charged phospholipids (such as cardiolipin, 
phosphatidyl serine, phosphatidyl inositol), Phospholipid-protein complexes, or 
plasma proteins (such as β2-glycoprotein).21 
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         The concept of a protein target for antiphospholipid antibodies evolved 
from a series of independent reports in 1990.  It became clear that the binding 
of the antibodies to cardiolipin required a cofactor, which was subsequently 
identified as β2 glycoprotein 1 also known as apolipoprotein H22,23,24 β2 
glycoprotein 1 is a highly glycosylated single chain plasma protein composed 
of 326 amino acids with a molecular weight of 50 kDa that appears to be the 
major, but not the only cofactor for the recognition of anionic phospholipid by 
antiphospholipid antibodies.  The protein is a member of the complement 
control protein or short consensus repeat super family.  There is evidence that 
β2GP1 itself may be one of the major epitopes for antiphospholipid antibodies 
or may, in complex with phospholipids, form an antigenic site.  The 
physiologic function of β2GP1 has not yet been established, but it has been 
proposed that the protein may play a scavenging role for exposed anionic 
phospholipid after apoptosis.25, 26 
         Following the discovery of the cofactor role for β2GP1, additional 
candidate cofactors and antigenic targets were identified.27, 28 
ANTIGENIC TRARGETS OF ANTIPHOSPHOLIPID ANTIBODIES 
Major antigens 
♦ β2-glycoprotein  
♦ Prothrombin 
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Others 
♦ Protein C  
♦ Protein S 
♦ Thrombomodulin 
♦ Annexin V 
♦ High/low molecular weight kininogen 
♦ Factor XI 
         A number of studies demonstrated that the β2GP1-dependent binding to 
phospholipids could be used to discriminate between autoimmune aPL and 
those found in patients following infections, aPL antibodies present in 
autoimmune diseases are thrombogenic and β2GP1 dependent, as opposed to 
infection related aPL antibodies, which are thought less likely to be 
thrombogenic and are β2GP1 independent.29  The presence of β2GP1 
dependent antibodies was shown to be more specific for thrombosis than 
conventional anti cardiolipin antibodies. 
CLASSIFICATION OF ANTIPHOSPHOLIPID THROMBOSIS 
SYNDROMES 
         Antiphospholipid thrombosis syndrome associated with anti cardiolipin 
antibodies is divided into one of six subgroups.30 Although there appears to be 
no correlation with the type or the titer of anti cardiolipin antibody and the type 
of the syndrome, the sub classification of thrombosis and anti cardiolipin 
antibody patients into these groups is important for therapy. 
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Type I syndrome 
         Deep venous thrombosis with or without pulmonary embolus. 
Type II syndrome 
         Coronary artery thrombosis 
         Peripheral artery thrombosis 
         Aortic thrombosis 
         Carotid artery thrombosis 
Type III syndrome 
         Retinal artery thrombosis 
         Retinal vein thrombosis 
         Cerebrovascular thrombosis 
         Transient cerebral ischemic attack 
Type IV syndrome 
         Mixture of types 1 2 3  
         Type IV patients are rare 
Type V (fetal wastage) syndrome 
         Placental vascular thrombosis 
         Maternal Thrombocytopenia (uncommon) 
         Fetal wastage common in first trimester 
         Fetal wastage can occur in second and third trimester 
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Type VI syndrome 
         Anti Phospholipid antibody 
         No apparent clinical manifestation 
         Most individuals with serum that reacts positively for anti Phospholipid 
antibodies do not have systemic lupus, but may have a history of thrombosis.  
However, the antibodies may also appear transiently after tissue trauma, in 
infections, and as a response to exposure to certain drugs.  
SITUATIONS IN WHICH ANTIPHOSPHOLIPID ANTIBODIES MAY 
BE DETECTED31 
Infections 
♦ Acute self-limiting infections 
♦ Syphilis 
♦ Malaria 
♦ HIV infection 
♦ Hepatitis C 
Rheumatic and collagen vascular diseases 
♦ Systemic lupus erythematosus 
♦ Systemic sclerosis 
♦ Rheumatoid arthritis 
♦ Temporal arteritis 
♦ Psoriatic arthropathy 
♦ Sjogrens syndrome 
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Thrombotic disease 
♦ Venous thrombembolic disease 
♦ Peripheral arterial occlusion 
♦ Microvascular thrombosis 
♦ Myocardial infarction and ischaemic heart disease 
♦ After coronary artery bypass graft surgery 
♦ Valvular heart disease 
♦ Renal vascular disease 
♦ Pulmonary hypertension 
Disorders of the nervous system and eye 
♦ Thrombotic stroke 
♦ Transient cerebral ischaemia and amaurosis fugax 
♦ Sagittal sinus thrombosis 
♦ Ischaemic optic neuropathy 
♦ Retinal venous occlusion 
♦  Multi infarct dementia 
♦ Chorea 
♦ Guillain-barre syndrome 
♦ Transverse myelitis 
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Obstetric disorders 
♦ Recurrent abortion 
♦ Fetal growth retardation 
♦ Early, severe pre-eclampsia 
With medication 
♦ Phenothiazines 
♦ Procainamide 
♦ Hydralazine 
♦ Phenytoin 
♦ Quinidine  
Miscellaneous 
♦ Livedo reticularis 
♦ Autoimmune Thrombocytopenia 
♦ Autoimmune hemolytic anaemia 
♦ Bechet’s syndrome 
♦ Sickle-cell disease 
♦ Intravenous drug abuse 
ASSOCIATION OF ANTICARDIOLIPIN ANTIBODIES WITH 
VASCULAR INJURY  
Possible Mechanisms 
♦ Endothelial activation 
♦ Accelerated atherosclerosis 
  25
♦ Apoptosis 
♦ Autoimmunity 
♦ Genetic predisposition 
ENDOTHELIAL ACTIVATION 
         Anti cardiolipin have been documented in subendothelial cardiac 
deposits.32 and in intimal-medial borders in isolated human atherosclerotic 
plaques.  The mechanism of anti cardiolipin associated  vasculopathy includes 
interaction of endothelial cells with platelets and antiphospholipid, to promote 
a cascade of reactions yielding recurrent local thrombosis and intimal 
hyperplasia.   
         Anticardiolipin auto antibodies prompt a prothrombotic endothelial 
surface,33 while the β2GP1 anti cardiolipin antibody complex activates 
endothelium in vitro.34  
         Antiphospholipid antibody binding to endothelium induces in vitro up-
regulation of adhesion molecules, such as intracellular adhesion molecule-1 
and extracellular adhesionmolecule-1, stimulated by an autocrine loop of 
interleukin-1β secretion.35  Platelet endothelium interaction mediated by 
anticardiolipin may alter thromboxane A2-prostacyclin balance, leading to 
enhanced thrombosis and vasoconstriction.36  Endodthelin-1, which induces 
vasospasm and arterial occlusion, is released by the endothelium in response to 
antiphospholipid antibodies.37 
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         A mechanism similar to heparin induced thrombocytopenia has also been 
suggested for anticardiolipin associated vascular occlusion and thrombosis.38 In 
addition to endothelial induced thrombosis, intimal hyperplasia plays a major 
part in vascular occlusions.  Endothelin prompted by anticardiolipin, enhances 
endothelial cell proliferation in vitro.39  
         Initial endothelial damage exposes the anionic phospholipids that react 
with the Phospholipid binding proteins, such as the β2GP1 or prothrombin.  
The simultaneous binding of aCL to cellular Fc receptor and Phospholipid 
protein complex induces endothelial platelet interaction resulting in 
thrombosis. 
ACCELERATED ATHEROSCLEROSIS 
         An intriguing possible pathogenic role for aCL in vasculopathy is the 
cross reaction with oxidized low density lipoprotein antibodies.  Oxidized LDL 
is the principal lipoprotein found in atherosclerotic lesions, and it co-localizes 
with β2GP1 and immunoreactive lymphocytes.40  Oxidized LDL binds to 
β2GP1 and that these complexes can be found in the blood stream of patients 
with various autoimmune and chronic inflammatory diseases such as the 
systemic lupus Erythematosus, chronic renal disease, diabetes mellitus, as well 
as in patients with cerebrovascular disease.41 
         As phospholipids bear structural resemblance to LDL, aCL may cross 
react with antioxidised LDL.42 Each cardiolipin molecule contains four 
unsaturated fatty acids, highly susceptible to oxidation. Mice sera with high 
titers of  oxidized  LDL  antibodies,  bind  cardiolipin  effectively  only  after  
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STRUCTURE OF  β2 GP1 LIGANDS DERIVED FROM OXIDISED 
LDL
  28
 
OXIDISED LDL UPTAKE  REGULATED BY IgG ANTI- β2GP1 
ANTIBODIES
COMPLEX FORMATION BETWEEN OXIDISED LDL AND β2 GP1 
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oxidation.Therefore, oxidative events may also play a major path in 
anticardiolipin formation.43  On the one hand, oxidized LDL aggravates in vitro 
the clinical manifestations of antiphospholipid andibody syndrome and on the 
other hand, atherogenic effect of human lupus sera in vitro may be mediated by 
LDL-containing immune complexes.  LDL may also be involved in 
anticardiolipin andibodies associated vascular occlusion by inducing a 
prothrombotic state.  LDL itself may be a thrombogenic target of 
anticardiolipin44 and raised concentrations of lipoprotein (a) in patients with 
antiphospholipid antibpdies may inhibit the fibrinolytic sspathway. 
APOPTOSIS 
         Hypercoagulability in patients with antiphospholipid antibodies may also 
be induced by apoptotic process.  Alterations of the Phospholipid phase of cell 
membranes during late apoptosis are immunogenic and associated with the 
production of antiphospholipid antibodies.  These surface alterations also have 
an independent procoagulant activity.45 Apoptotic cells may promote 
coagulation directly or via athersclerotic plaque dislodgement.   
         Characteristic membrane blobbing, occurring in final stages of apoptosis 
may lead to the production of antiphospholipid antibodies and tissue factor 
procoagulant activity.  Moreover, it has been claimed that via this pathway 
antiphospholipid antibodies may exert their hypercoagulability.  Apoptotic 
inflammatory cells, such as the macrophages and T cells, are found abundantly 
in ahterosclerotic plaques and may induce plaque instability.  Endothelial cell 
apoptosis may lead to loss of anticoagulant  activity and increased leukocyte 
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and platelet adhesion, resulting in rapid progression of the atherosclerotic and 
calcification process.45 On the other hand, antiphospholipid antibodies may 
enhance apoptosis, with nuclear DNA fragmentation, cell lysis, and membrane 
disruption.   
AUTO IMMUNITY 
         Pathogenicity of antiphospholipid antibody syndrome depends on 
specificity, isotype and level of these antibodies .46 Cross regulatory roles of 
immunity and autoimmunity have recently emerged in vasculopathic and  
atherosclerotic processes.47  A prerequisite for this vascular autoimmunity is a 
humoral or cellular immune reactivity to self antigens,48 such as LDL turned 
immunogenic during oxidation and glycation and prompting T cell mediated 
immunity. 
GENETIC PREDISPOSITION 
         Most anticardiolipin antibodies are species-specific recognizing only 
human plasma.  They are associated with class 2 major histocompatibility 
complex and in particular the DQB1 locus and DRw53 and either DR4 (in 
Caucasians) or DR7 (in Latinos).  Genetic factors probably play an important 
part in the thrombogenic  mechanism of antiphospholipids.  Therefore, 
anticardiolipin antibodies may occur in genetically or immunologically 
susceptible patients after a common infection or after recurrent endothelial 
results and local thrombosis. 
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CLINICAL PICTURE OF ATHEROTHROMBOTIC STROKE 
 In general, the evolution of clinical phenomena in relation to cerebral 
thrombosis is more variable than that of embolism and hemorrhage. In more 
than half of our patients, the main part of the stroke (paralysis or other deficit) 
is preceded by minor signs or one or more transient attacks of focal neurologic 
dysfunction, or TIAs. In a sense, these herald the oncoming vascular 
catastrophe. A history of such prodoromal episodes is of paramount importance 
in establishing the diagnosis of atherothrombotic stroke. Only rarely and for 
unclear reasons of atherothrombotic stroke. Only rarely and for unclear reasons 
are embolism and cerebral hemorrhage preceded by a transient neurologic 
disorder. 
 In carotid and middle cerebral artery disease, the transient attacks 
consist of monocular blindness or of hemiplegia, hemianesthesia, or 
disturbances of speech and language. In the vertebrobasilar system, the 
prodromal spells most often take the form of episodes of vertigo, diplopia, 
numbness, impaired vision in one or both visual fields, and dysarthria. Such 
attacks last from from a few minutes to several hours; in most instances the 
duration is less than 10 min. The final stroke may be preceded by one or two 
attacks or a hundred or more brief TIAs, and the stroke may follow the onset of 
the attacks by hours, days, or less frequently by weeks or months. When there 
are no prodromal ischemic attacks, one must use other criteria to establish the 
diagnosis of atherosclerotic thrombosis. 
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Sl. 
No. Clinical Presentation Percent 
1. Transient ischemic attacks progressing to a major 
or minor presistent neurologic deficit. 
42 
2. Stepwise development of a stroke, with or 
without transient ischemic attacks. 
18 
3. Stroke developing as a single event : Abrupt 
(hours), with or without fluctuations 
11 
4. Slow, gradual (a few days), with or without 
minor fluctuations 
6 
5. Transient ischemic attacks only 14 
6. Development of a limited stroke followed by 
transient ischemic attacks 
9 
 
 The thrombotic stroke, whether or not it is preceded by warning attacks, 
finally develops in one of several ways. Most often there is a single episode but 
the whole illness evolves over a few hours or less. More characteristic is a 
"stuttering" or intermittent a day or longer. This a starkly different profile from 
the abrupt onset of  a complete stroke syndrome that characterizes the embolic 
mechanism. Again, in thrombosis a partial stroke may occur and even recede 
temporarily for several hours, after which there is rapid progression to the 
completed stroke – or several fleeting episodes may be followed by a longer 
one and, hours or a day or two later, by a major stroke. Several parts of the 
body may be affected at once or only one part, such as a limb or one side of the 
face, the other parts becoming involved serially in step-like fashion until the 
stroke is fully developed. Sometimes the deficit is episodic; spells of weakness 
or involuntary movement of a hand or arm or dimness of vision, lasting 5 to 10 
min. occur spontaneously or are brought on by standing or walking. Each of the 
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transient attacks and the abrupt episodes of progression reproduces the profile 
of the stroke in miniature. The principle of intermittency seems to characterize 
the thrombotic process from beginning to end. 
 As frequent as the modes of onset outlined above, and most 
characteristic of atherombotic events, is the occurrence of the stroke during 
sleep; the patient awakens paralyzed, either during the night or in the morning. 
 Most deceptive of all are the relatively few patients in whom the 
neurologic disorder has evolved over several days or even longer, in a slow, 
gradual fashion ("slow stroke"). One's first impulse is to make a diagnosis of 
brain tumor, abscess, or subdural hematoma. This error can usually be avoided 
by a careful analysis of the course of the illness, which will disclose an uneven, 
saltatory progression; if the clinical data are incomplete, observation for a few 
days makes the stroke profile more apparent. Actually there are a few cases – 
and these are usually instances of pure motor hemiplegia – in which the 
evolution of a thrombotic stroke is evenly progressive over a period of days. 
 In addition to these several modes of evolution of atherothrombotic 
stroke, thrombotic stenosis or occlusion of certain large vessels may lead 
instead to the generation of embolic fragments (artery-toartery embolus), 
thereby precipitating a new stroke in a region distal to the occlusion. This is 
most likely to occur during the period of clinical fluctuation and active 
thrombus formation. The most common occurrence of artery-to-artery 
embolism is with carotid artery thrombosis, the embolus passing to branches of 
the ipsilateral middle or anterior cerebral artery. With atherothrombotic 
blockage of the vertebral or lower basilar artery, the embolus originates in the 
occluded vessel but then proceeds to lodge in the posterior cerebral artery or 
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the top of the basilar artery. In most of the cases of this nature, there are 
additional telltale signs of slight pontine strokes (dysarthria, diplopia), 
presumably from the transient occlusion of the mouths of several small 
penetrating arteries as the embolus moves upward ("stop-and-go" or "traveling" 
embolus syndrome). 
CAROTID ARTERY OCCLUSION  
 Common carotid occlusion accounts for less than 1 percent of cases of 
carotid artery syndrome – the remainder being due to disease of the internal 
carotid artery itself. Nevertheless, the common carotid can be occluded by an 
atheromatous plaque at its origin, more often on the left side. Atherosclerotic 
stenosis or occlusion of the midportion of the common carotid may also occur 
years after radiation therapy for laryngeal or other head and neck cancer. If the 
bifurcation is patent, few if any symptoms may result, in some cases because 
retrograde flow from the external carotid maintains internal carotid flow and 
perfusion of the brain. 
 The syndrome caused by common carotid occlusion are identical to 
those of its internal branch. The clinical manifestations of atherosclerotic 
thrombotic disease of internal carotid artery are among the most variable of any 
cerebrovascular syndrome. Unlike other cerebral vessels, the internal carotid 
artery is not an end vessel. In most individuals it is in continuity with the 
vessels of the circle of Willis and those of the orbit, and no part of the brain is 
completely dependent on it. Therefore occlusion, which occurs most frequently 
in the first part of the internal carotid artery (immediately beyond the carotid 
bifurcation), is often silent (30 to 40 percent of cases).  
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 Headache – located as a rule, above the eyebrow – may occur with 
thrombosis or embolism of the carotid artery, but cranial pain is not invariable. 
The headache sometimes associated with occlusion of the middle cerebral 
artery tends to be more lateral, at the temple; that of posterior cerebral 
occlusion is in or behind the eye. 
 When the circulation of one carotid artery has been incompletely 
compromised, reducing blood flow in both the middle and anterior cerebral 
territories, the zone of maximal ischemia lies between the two vascular 
territories ("cortical watershed") or, alternatively, in the deep portions of the 
hemisphere, between the territories of the lenticulostriate branches and the 
penetrating vessels from the convexity ("internal or deep watershed"). The 
infarction in the first instance occupies a region in the high parietal and frontal 
cortex and subcortical white matter. Its size depends upon the adequacy of 
collateral vessels. The weakness that results tends to involve the shoulder and 
hip more than the hand and face. With long-standing carotid stenosis, the 
carotid watershed zone tends to shift downward toward the perisylvian portions 
of the middle cerebral artery territory, even to the extent of affecting facial 
movement or causing a motor aphasia. The frequent sparing of the posterior 
part of the hemisphere is reflected in the low incidence of Wernicke types of 
aphasia and of homonymous hemianopia. With impaired perfusion of the so-
called internal watershed, infarctions of varying size are situated in the 
subfrontal and subparietal portions of the centrum semiovale. 
 The internal carotid artery nourishes the optic nerve and retina as well as 
the brain. For this reason, transient monocular blindness occurs prior to the 
onset of stroke in 10 to 25 percent of cases of symptomatic carotid occlusion. 
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Yet central retinal artery ischemia is a relatively rare manifestation of carotid 
artery occlusion, presumably because of efficeint collateral supply in the globe. 
With severe atherosclerotic stenosis at the level of the carotid sinus, with or 
without a superimposed thrombus, auscultation frequently discloses a bruit, 
best heard with the bell of the stethoscope. If the bruit is loudest at the angle of 
the jaw, the stenosis usually lies at the proximal internal carotid; if heard lower 
in the neck, it is in the common carotid or subclavian artery. Rarely, stenosis in 
vertebral arteries or vascular malformations at the base of the brain may 
produce bruits posteriorly in the neck. 
 The duration and quality of the bruit are relevant – bruits that extend 
into diastole and are high-pitched are almost invariably associated with a tight 
stenosis (lumen < 1.5 mm). An additional though infrequent sign of carotid 
occlusion is the presence of a bruit over the opposite carotid artery, heard best 
by placing the bell of the stethoscope over the eyeball (ocular bruit). Pulsation 
may be palpably reduced or absent in the common carotid artery in the neck, in 
the external carotid artery in front of the ear, and in the internal carotid artery in 
the lateral wall of the pharynx, but these are among the least dependable signs 
of carotid disease. 
DIAGNOSIS 
 In the laboratory investigation of atherothrombotic infarction, one may 
employ non-invasive techniques. 
¾ Ultrasonography  : will reveal with fair accuracy the cervical and 
intracranial segments of the internal carotid and vertebrobasilar arteries. 
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¾ Computed Tomography : CT imaging is mandatory for proper initial 
evaluation in all cases of stroke to categories them into either ischemic 
(or) haemorrhagic origin. 
1. To confirm diagnosis (Haemorrhage can be detected immediately 
whereas it may take two days for infarcts to the detected). 
2. To decide the line of management (to decide on therapy with 
anticoagulants (or) anti platelet drugs). 
3. To identify the presence of underlying tumour, haematoma (or) 
vascular malformation which can stimulate stroke. 
CT FINDINGS IN CEREBRAL INFARCTION 
Stage of infarct CT findings 
Hyper acute (< 12 
hours)  
Normal (50 to 60%), hyperdense artery (25 to 
50%), obscuration of lentiform nuclei 
Acute (12 to 24 hours) Low density basal ganglia, loss of grey-white 
matter interface (insular ribbon sign), sulcal 
effacement 
1 to 7 days Mass effect, wedge shaped low density area 
involving white and gray matter, haemorrhagic 
transformation, gyral enhancement 
1 to 8 weeks Contrast enhancement persists, mass effect resolves 
Months to years Encephalomalacic change, volume loss, rarely 
calcification. 
 
¾ Magnetic Resonanace Imaging  : MRI is more sensitive to ischemic 
brain damage than is the CT scan. While the later reveals hemorrhage 
immediately after it occurs, softened tissue cannot be seen until several 
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days have elapsed. On the other hand, MRI reveals ischemic damage 
with in a few hours, in both white and grey matter,  and diffusion – 
weighted MRI techniques do so even earlier. The various MRI 
sequences are able to distinguish with reasonable clarity the age of 
cerebral infarction. 
¾ Opthalmic dynamometry : A diastolic  retinal pressure of less than 20 
mmHg. Usually means that the common or internal carotid artery is 
occluded. 
¾ Blood Sugar  
¾ Serum Cholesterol, Triglycerides . 
¾  ECG (Electrocardiography) : Reflecting a previous myocardial 
infarction or left ventricular hypertrophy. 
¾ EEG (Electroencephalogram)  : It is of value in distinguishing large 
strokes from lacunes. 
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MATERIALS AND METHODS 
This study was an observational study conducted on a total of 35 
patients admitted in the Intensive Medical Care Unit and General Medical 
Wards at Government Stanley Hospital, Chennai.  The period of study was 
about 8 months (From July 2006 to March 2007). 
Selection Criteria 
         Patients with the age of < 55 years of either sex who admitted with the 
acute onset of focal neurological deficit with the CT brain showing infarction 
were included in the study. 
         The prevalence of positive ELISA antiphospholipid antibody titer 
increases with age.  Most data deal with anticardiolipin antibodies, which have 
been reported in 12 – 52% of apparently healthy elderly aged more than 65 
years 49,50.  Hence, a cutoff age of 55 was considered in the study group. 
         35 age and sex matched apparently healthy persons served as control.  
Conventional cerebrovascular risk factors such as hypertension, diabetes, 
smoking and alcohol were determined by a thorough history taking.  The blood 
samples are taken on the 2nd day of hospitalization after getting the consent 
from the patients.  The quantitative measurement of IgG and IgM class 
autoantibodies against cardiolipin in human serum (or) plasma was determined 
by an indirect solid phase enzyme immunoassay (ELISA).  
         Data were analyzed using Pearson Chi square test and Yates corrected chi 
square test. 
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NAME OF THE TEST 
         It is an indirect solid phase enzyme immunoassay (ELISA) for the 
quantitative measurement of IgG and IgM class autoantibodies against 
cardiolipin in human serum or plasma. 
PRINCIPLE 
         Highly purified cardiolipin is bound to micro wells saturated with β2 
glycoprotein 1.  Antibodies to these antigens, if present in diluted serum, bind 
in the micro wells.  Washing of the micro wells removed unbound serum 
antibodies.  Horseradish peroxidase (HRP) conjugated anti human IgG and 
IgM immunologically bind to the bound patient antibodies forming a 
conjugate/antibody/antigen complex.  Washing the micro wells removes 
unbound conjugate.  An enzyme substrate in the presence of bound conjugate 
hydrolyzes to form a blue color.   The addition of an acid stops the reaction 
forming a yellow product.  The intensity of this yellow color is measured 
photometrically at 450 nm.  The amount of color is directly proportional to the 
concentration of IgG and IgM antibodies present in the original sample. 
STORAGE AND STABILITY 
¾ Store the kit at 2 – 8oC. 
¾ Keep micro plate wells sealed in a dry bag with desiccants. 
¾ The reagents are stable until expiration of the kit 
¾ Do not expose the test reagents to heat, sun or strong light during 
storage and usage. 
¾ Diluted sample buffer and wash buffer are stable for at least 30 days 
when stored at 2 – 8oC. 
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MATERIALS REQUIRED 
Equipment 
 Micro plate reader capable of end point measurements at 450 nm. 
 Multi-channel dispenser or repeatable pipette for 100 µl 
 Vortex mixer 
 Laboratory timing device 
 Data reduction software 
Preparation of reagents 
 Distilled or deiodinised water 
 Graduated cylinder for 100 and 100 ml 
 Plastic container for storage of the wash solution. 
SPECIMEN COLLECTION, STORAGE AND HANDLING 
♦ Collect whole blood specimens using acceptable medical techniques to 
avoid hemolysis. 
♦ Allow blood to clot and separate the serum by centrifugation. 
♦ Test serum should be clear and non-hemolysed. Contamination by 
hemolysis or lipemia is best avoided, but does not interfere with this 
assay. 
 
  42
♦ Specimens may be refrigerated at 2 – 8oC for up to 5 days or stores at      
–20oC for up to six months. 
♦ Avoid repeated freezing and thawing of serum samples.  This may result 
in variable loss of autoantibody activity. 
♦ Testing of heat-inactivated sera is not recommended. 
PREPARATION OF THE REAGENTS 
Preparation of the sample buffer 
         Dilute the contents of each vial of the sample buffer concentrate with 
distilled or deiodinised water to a final volume of 100 ml prior to use.  Stores 
refrigerated: stable at 2 – 8oC for at least 30 days after preparation of until the 
expiration date printed on the label. 
Preparation of the wash solution 
         Dilute the contents of each vial of the buffered wash solution concentrate 
with distilled or deiodinised water to a final volume of 1000 ml prior to use.  
Store refrigerated: stable at 2 – 8oC for at least 30 days after preparation or until 
the expiration date printed on the label. 
Sample preparation 
         Dilute all patient samples 1:100 with sample buffer before assay.  
Therefore, combine 10µl of sample with 990µl of sample buffer in a 
polystyrene tube.  Mix well.  Controls are ready to use and need not be diluted. 
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TEST PROCEDURE 
1. Prepare a sufficient number of micro plate modules to accommodate 
controls and pre diluted patient samples. 
2. Pipette 100µl of calibrators, controls and pre diluted patient samples in 
duplicate into the wells. 
3. Incubate for 30 minutes at room temperature (20 – 28oC). 
4. Discard the contents of the micro wells and wash 3 times with 300µl of 
wash solution. 
5. Dispense 100µl of enzyme conjugate into each well. 
6. Incubate for 15 minutes at room temperature 
7. Discard the contents of the micro wells and wash 3 times with 300µl of 
was solution. 
8. Dispense 100µl of TMB (3,3’, 5,5’ –tetramethyl-benzidine) substrate 
solution into each well. 
9. Incubate for 15 minutes at room temperature. 
10. Add 100µl of stop solution to each well of the modules and incubate for 
15 minutes at room temperature. 
11. Read the optical density at 450 nm and calculate the results.  Bi-chromatic 
measurement with a reference at 600 – 690 nm is recommended. 
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12. The developed color is stable for at least 30 minutes.  Read optical 
densities during this time. 
INTERPRETATION OF RESULTS 
         In a normal range study with serum samples from healthy blood donors 
the following ranges have been established with the anti-cardiolipin test. 
ANTI CARDIOLIPIN ANTIBODIES 
 IgG (GPL U/ml) IgM (MPL U/ml) 
NORMAL < 10 < 7 
POSITIVE > 10 >7 
 
Quality control 
         This test is only valid if the optical density at 450 nm for positive control 
and negative control as well as for the calibrator A and F complies with the 
respective range indicated on the quality control certificate enclosed to each 
test kit.  If any of these criteria is not met, results are invalid and the test should 
be repeated. 
Calculation of the results 
         For anti cardiolipin IgG and IgM, a 4 parameter fit with lin-log 
coordinates for optical density and concentration is the data reduction method 
of choice.  Smoothed spline approximation and log-log coordinates are also 
suitable. 
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Recommended Lin-Log plot 
         First calculate the averaged optical densities for each caliber well.  Use 
lin-log graph paper and plot the averaged optical density of each calibrator 
versus the concentration.  Draw the best fitting curve approximating the path of 
all calibrator points.  The calibrator points may also be connected with straight-
line segments.  The concentration of unknowns may then be estimated from the 
calibration curve by interpolation. 
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OBSERVATIONS AND RESULTS 
         In the present study, among the 35 cases, the age distribution ranged from 
35 – 56 years.  Since age is a major risk factor for cerebrovascular disease, the 
cases were subdivided into two groups with 45 as the line of demarcation 
between them.  Acute ischemic stroke occurred predominantly in males when 
compared to females in our study. 
TABLE 1 
GENDER DISTRIBUTION OF THE STUDY POPULATION 
 MALE FEMALE 
STUDY GROUP (35) 30 (85.7%) 5 (14.3%) 
 
TABLE 2 
AGE DISTRIBUTION OF THE STUDY POPULATION 
 AGE > 45 AGE <=45 
STUDY GROUP   19 (54.3%) 16(45.7%) 
 
         The presence of the conventional cerebrovascular  risk factors in the 
study population and its distribution was analysed.  Of the four risk factors 
(Hypertension, Diabetes Mellitus, Smoking, Alcohol) that were considered, 
smoking and Alcohol were widely prevalent in the study group. 
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TABLE 3 
DISTRIBUTION OF DIABETES MELLITUS AMONG THE CASES 
 DIABETICS  NON-DIABETICS 
STUDY GROUP  9 (25.7%) 26(74.3%) 
 
 
TABLE 4 
DISTRIBUTION OF HYPERTENSION AMONG THE CASES 
 HYPERTENSIVES NON-HYPERTENSIVES 
STUDY 
GROUP  
10(28.6%) 25(71.4%) 
 
 
TABLE 5 
DISTRIBUTION OF SMOKING AMONG THE CASES 
 SMOKERS  NON-SMOKERS 
STUDY GROUP   23(65.7%) 12(34.3%) 
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TABLE 6 
DISTRIBUTION OF THE β2GP1 DEPENDENT ANTICARDIOLIPIN 
ANTIBODY POSITIVITY AMONG THE CASES AND CONTROLS 
 ANTIBODY 
POSITIVITY 
ANTIBODY 
NEGATIVITY 
STUDY GROUP   10(28.6%) 25(71.4%) 
CONTROL GROUP 2(5.7%) 33(94.3%) 
 
Error!  X2 = 6.44  p = 0.01  (Statistically significant) 
 The antibody positivity was compared between the cases and the 
controls.  The β2 glycoprotein1 dependent anticardiolipin antibodies were 
found to be positive in 10 patients in the study group whereas 2 people tested 
positive in the control group. The antibody positivity was statistically 
significant in the study group. 
TABLE 7 
ISOTYPE DISTRIBUTION OF ANTIBODY POSITIVITY IN CASES 
AND CONTROLS 
 STUDY GROUP CONTROL GROUP 
IgG POSITIVITY 6 0 
IgM POSITIVITY 3 2 
IgG & IgM POSITIVITY 1 0 
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         Isotype distribution of anticardiolipin antibodies namely IgG and IgM 
was studied in both the groups.  IgG was the predominant isotype in the study 
group.  A total of 6 patients were found to have IgG antibody positivity. 3 
patients showed IgM positivity while one had elevation of both the isotypes. 
TABLE 8 
IgG β2GP1 ANTICARDIOLIPIN ANTIBODY IN CASES AND 
CONTROLS 
 IgG POSITIVITY IgG NEGATIVITY 
STUDY GROUP   7 28 
CONTROL GROUP 0 35 
 
X2 = 7.78  p = 0.005 (Statistically significant) 
         The significance of the antibody isotypes was then analysed across both 
the groups.  It was found that the isotype  IgG positivity was statistically 
significant in the study group when compared to the control group.  The IgM 
positivity did not show any significant difference between the two groups. 
TABLE 9 
IgM β2GP1 ANTICARDIOLIPIN ANTIBODY IN CASES AND 
CONTROLS 
 
 IgM POSITIVITY IgM NEGATIVITY 
STUDY GROUP   4 31 
CONTROL GROUP 2 33 
Error! 
X2 Y=0.73  p = 0.39 (Not significant) 
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         The conventional risk factors were then correlated with antibody 
positivity.  Diabetes Mellitus was the only factor that was significantly 
observed in the study group. 
 
TABLE 10 
DIABETES MELLITUS AND ANTICARDIOLIPIN POSITIVITY 
 ANTIBODY 
POSITIVITY 
ANTIBODY 
NEGATIVITY 
DIABETES MELLITUS  5 4 
NON-DIABETES 
MELLITUS 
5 21 
 
TABLE 11 
HYPERTENSION AND ANTICARDIOLIPIN ANTIBODIES 
 ANTIBODY 
POSITIVITY 
ANTIBODY 
NEGATIVITY 
HYPERTENSIVES 4 6 
NON-HYPERTENSIVES 6 19 
 
X2 = 0.90  p = 0.34 (Not significant) 
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TABLE 12 
SMOKING AND ANTICARDIOLIPIN ANTIBODIES 
 ANTIBODY 
POSITIVITY 
ANTIBODY 
NEGATIVITY 
SMOKERS 5 18 
NON-SMOKERS 5 7 
 
X2 = 1.53  p = 0.21 (Not significant) 
TABLE 13 
SEX AND ANTICARDIOLIPIN ANTIBODIES POSITIVITY 
 ANTIBODY 
POSITIVITY 
ANTIBODY 
NEGATIVITY 
MALE 8 22 
FEMALE 2 3 
 
X2 = 0.37  p = 0.54 (Not significant) 
TABLE 14 
AGE AND ANTICARDIOLIPIN POSITIVITY 
 
 ANTIBODY 
POSITIVITY 
ANTIBODY 
NEGATIVITY 
AGE > 45 5 14 
AGE < 45 5 11 
 
X2 = 0.10  p = 0.74 (Not significant) 
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DISCUSSION 
         Anti cardiolipin antibodies are most commonly found in patients with 
systemic lupus erythematosus and antiphospholipid antibody syndrome.  
However, they are not specific to systemic lupus erythematosus and 
antiphospholipid antibody syndrome and may occur in normal subjects, 
patients with other autoimmune disorders, malignancy, HIV infection and 
drugs51,52 .  Levine reported the association between anticardiolipin antibodies 
and stroke. It has been well established in patients with primary APL syndrome 
and systemic lupus erythematosus associated secondary APL syndrome, but a 
growing body of evidence supports an association in unselected patients as 
well53.   
         The cumulative prevalence rates for increased anticardiolipin antibody 
titer in ischemic stroke patients were relatively high (In all ages 17%, age < 50 
years  21%)54.   
         Reyes H states that APL antibodies have been found in upto 14% of 
normal subjects55,56,57.  Nagaraj et al in a study of 60 cases of young stroke 
found elevated anticardiolipin in 23% of patients58.  Some studies have found 
widely varying frequencies of anticardiolipin antibodies in patients with stroke 
with the prevalence from 1 to 50%. 
         Mehndiratta and Bhattacharya reported that the prevalence of 
antiphospholipid antibodies in healthy people is 4.3%, whereas in stroke 
patients it is about 1 to 46% depending upon the design and criteria of studies 
and the age distribution of patients59. 
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         A number of studies demonstrated that the β2GP1 dependent binding to 
phospholipids could be used to discriminate between autoimmune 
anticardiolipin and those found in patients following infections.  
Anticardiolipin antibodies  present in autoimmune diseases are thrombogenic 
and β2GP1 dependent, as opposed to infection related anticardiolipin 
antibodies, which are thought less likely to be thrombogenic and are β2GP1 
independent. So, the presence of β2GP1 antibodies was shown to be more 
specific for thrombosis than conventional anticardiolipin antibodies. 
         In the population that we examined, a prevalence of 28.6% β2GP1 
dependent anticardiolipin positive patients were found.  This figure is 
significantly higher than the 5.7% observed in the control group (p=0.01). 
However, IgM β2GP1 dependent anticardiolipin antibodies were not 
significantly increased in the study group. 
         Here, we found a notable, although not significant difference in the 
frequencies of β2GP1 dependent anticardiolipin antibodies between males and 
females (26.6%) verses 40%, respectively.  But females contributed only about 
14.3% of the study population. 
         When we divided our patients into two groups, based on age (group 1 age 
> 45, group II age < 45) there was no significant difference in the frequencies 
of β2GP1 dependent anticardiolipin antibodies between them. 
         We found significantly higher frequencies of β2GP1 dependent 
anticardiolipin antibodies among the patients with diabetes mellitus.  However, 
we did not find any significant association between β2GP1 dependent 
anticardiolipin antibodies positivity and other conventional cerebrovascular 
risk factors like Hypertension and smoking. 
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         There are a good number of studies that looked into the prevalence of 
anticardiolipin antibodies of isotypes IgG and IgM in patients with ischemic 
stroke and its relationship with other risk factors. 
         Robin, L. Brey et al performed a nested case control study examining 
anticardiolipin as a risk factor for ischemic stroke and myocardial infarction by 
using stored frozen sera obtained from subjects enrolled in Honolulu heart 
programme and followed up for 20 years. The β2GP1 dependent anticardiolipin 
of the class IgG was significantly associated with both ischemic stroke and 
myocardial infarction60. 
         D’olhaberriague et al reported significantly increased odds of 
anticardiolipin positivity in ischemic stroke patients compared with patients 
with the other neurological diseases, suggesting that the antibodies are specific 
to stroke61.   
         Tannel et al reported that anticardiolipin IgG titers are associated with the 
presence of multiple stroke risk factors such as age > 65 years, atrial 
fibrillation, valvular heart disease, congestive heart failure62. 
         Brey et al demonstrated an association between β2GP1 dependent 
anticardiolipin and incidence of ischemic stroke.  Their results showed that 
patients with IgG β2GP1 dependent anticardiolipin had a two fold increase in 
odds of stroke with in 15 years of follow up when compared with 
anticardiolipin negative individuals.  This study also gives further evidence for 
the role of anticardiolipin as an independent risk factors for ischemic stroke in 
the general population63. 
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         Levine suggested that IgG is the anticardiolipin most commonly seen 
with antiphospholipid antibody positive stroke.  Young stroke patients have 
higher levels of antiphospholipid antibodies and multiple infarctions than 
general stroke population64.    Finazzi G and Branacaccio found the presence of 
high titre of anticardiolipin immuno reactivity mainly IgG isotype but possible 
IgM also correlates with an increased risk of thrombosis.  A study which was 
undertaken by Tuhrim et al showed that the elevated anticardiolipin antibody 
titer is a stroke risk factor in a multi ethnic population independent of isotype 
(or) degree of positivity.  He also states that anticardiolipin antibodies 
conferred a four fold increased risk of ischemic stroke65.   
         Few studies have shown increased incidence of recurrent ischemic stroke 
in patients with high anticardiolipin antibody titer positivity.  Patients with 
elevated IgG anticardiolipin levels had the shortest times to subsequent 
thrombo occlusive events, mainly represented by cerebral infarction often 
occurring within the first year of follow up supporting that IgG anticardiolipin 
represented a risk factor for recurrent stroke. 
         A recent study of APASS (Antiphospholipid Antibodies and Stroke 
Studies) found that a single anticardiolipin antibody value > 10 GPL units at 
the time of initial ischemic stroke was a significant independent risk factor for 
stroke.  When titer is high > 40  GPL units recurrence is common66.   
         Since anticardiolipin antibodies are a novel modifiable risk factors for 
stroke, some of the studies has been undertaken to know its therapeutic 
significance. 
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         Panagariya et al analysed 12 stroke patients with anticardiolipin antibody 
positivity and found that both the IgG and IgM class anticardiolipin antibodies 
were raised equally.  Therapeutic option in patients with stroke and increased 
anticardiolipin antibodies include antithrombotics and immune based treatment. 
         In his series, patients with first episode of stroke were put on aspirin (or) 
ticlopidine.  Patients with recurrent events were put on oral anticoagulants.  All 
patients recovered to normal functional capacity and did not have recurrence67. 
         APASS study states that nevertheless in those with persistently high titer 
of anticardiolipin (or) persistently positive lupus anticoagulant and some 
features of the antiphorpholipid antibody syndrome there does seem to be an 
association between anticardiolipin antibodies and stroke.  In such patients 
anticoagulation with an INR > 3 seems to be more effective than low intensity 
warfarin (or) aspirin in preventing recurrent thrombosis.   
Mehndiratta and Bhattacharrya 59 stated that there are no clear 
recommendations about the duration of the therapy but consensus could favors 
the lifelong treatment with antiplatelet drugs (or) anticoagulants to prevent 
recurrences in stroke patients with antiphospholipid antibodies positivity. 
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CONCLUSION 
 The prevalence of β2 glycoprotein1 dependent anticardiolipin antibodies 
of isotyes IgG/IgM was found to be 28.6% (p = 0.01). 
 IgG β2 glycoprotein1 dependent anticardiolipin antibodies was the most 
relevant isotype associated with acute ischemic stroke (p = 0.005). 
 Patients with Diabetes Mellitus had a higher frequency of β2 
glycoprotein dependent anticardiolipin antibodies (p = 0.04). 
 β2 glycoprotein1 dependent anticardiolipin antibodies did not show a 
significant association with other conventional risk factors like 
Hypertension, smoking, alcohol and age.  
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PROFORMA 
“PREVALENCE OF  β2 GLYCOPROTEIN 1   DEPENDENT ANTICARDIOLIPIN 
ANTIBODIES IN ACUTE ISCHEMIC STROKE” 
 
Name      : 
Age      : 
Sex      : 
Clinical Presentation    
Risk Factors      
Diabetes Mellitus   : 
Systemic Hypertension  : 
Smoking    : 
Alcohol    : 
Heart Diseases   : 
Obesity    : 
Others       
Investigations     
Hb     : 
ESR     : 
Platelet count   : 
B-Sugar    : 
 S-Cholesterol   : 
CRP     : 
ANA     : 
Rh-Factor    : 
ECG     : 
ECHO    : 
CT Brain    : 
 
β2 GP1 Dependent Anticardiolipin Antibodies 
 -  IgG     : 
 - IgM     : 
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1 VEERAMANI 0 1 0 1 1 1 1 0 1 SUBRAMANIYAN 1 1 0 0 0 0 0 0
2 KHADAR 0 1 1 1 1 1 1 0 2 VADIVELU 0 1 0 0 1 0 0 0
3 KUPPAN 1 1 1 1 1 1 1 0 3 GODANDARAMAN 0 1 0 0 0 0 0 0
4 PONNUSAMY 0 1 0 0 0 0 0 0 4 RAGHAVAN 0 1 0 0 0 1 0 0
5 AKRAM 0 1 0 0 1 0 0 1 5 MUNUSAMY 0 1 0 0 0 0 0 0
6 GOVINDAN 1 1 0 0 1 1 0 0 6 KUZHANTHIVELU 1 1 0 0 0 0 0 0
7 VASU 1 1 1 0 0 1 1 1 7 SIVAGURU 1 1 0 0 1 1 0 0
8 IRUDAYAN 1 1 0 1 1 1 0 0 8 KANNIYAPPAN 0 1 0 0 1 0 0 0
9 KALI 0 1 0 0 1 1 0 0 9 PANNERSELVAN 0 1 0 0 0 0 0 0
10 ELUMALAI 1 1 1 0 1 1 0 0 10 NATARAJAN 1 1 0 0 0 0 0 0
11 ANTONY 0 1 0 0 1 1 0 0 11 PALANISAMY 0 1 0 0 0 1 0 0
12 MANI 1 1 0 0 1 1 0 0 12 SENDHILNADHAN 0 1 0 0 0 0 0 0
13 BASHA 1 1 0 1 1 1 0 0 13 MANIKANDAN 1 1 0 0 0 0 0 0
14 RAVI 1 1 0 1 1 0 0 0 14 VENKATESAN 1 1 0 0 0 0 0 0
15 SOUKANTHALI 0 1 0 0 1 1 0 0 15 ARUNAGIRI 1 1 0 0 1 0 0 0
16 PICHAIAN 0 1 1 0 1 1 0 0 16 KARUNANITHI 0 1 0 0 1 1 0 0
17 KANNAN 1 1 0 0 1 1 0 0 17 ANBHAZHAGAN 0 1 0 0 0 0 0 0
18 MUNUSAMY 0 1 0 0 1 1 0 0 18 MURUGESAN 1 1 0 0 0 0 0 0
19 SHANMUGAM 0 1 0 1 1 1 0 1 19 NARAYANAN 1 1 0 0 0 0 0 0
20 MUTHUKRISHNAN 0 1 0 1 0 1 0 0 20 RAJA 0 1 0 0 0 0 0 0
21 MANI 1 1 0 0 0 0 0 1 21 KALAIARASAN 1 1 0 0 1 0 0 0
22 RAMASAMY 0 1 1 0 1 1 0 0 22 MANIKKAM 0 1 0 0 0 1 0 0
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STUDY GROUP CONTROL GROUP
23 JAYAVEL 1 1 0 0 1 1 0 0 23 RAJENDIRAN 0 1 0 0 0 0 0 0
24 SUNDARAJAN 1 1 0 0 0 1 0 0 24 SUBBIAH 1 1 0 0 1 0 0 0
25 SAMIKANNU 0 1 0 0 1 0 0 0 25 BASHEER AHMED 1 1 0 0 0 0 0 0
26 SIVARAJAN 0 1 0 0 1 0 0 0 26 JAYAKUMAR 1 1 0 0 0 1 0 0
27 RAJA 1 1 0 0 0 1 1 0 27 SARAVANAN 0 1 0 0 0 1 0 0
28 SUBRAMANI 0 1 0 0 1 1 0 0 28 JOHNBABU 0 1 0 0 0 0 0 0
29 MUNIVEL 0 1 0 0 0 1 0 0 29 SUNDERESAN 1 1 0 0 1 0 0 0
30 RAGAVEL 1 1 1 0 1 0 0 0 30 ASHOGAN 0 1 0 0 0 0 0 0
31 KASTHURI 0 0 0 1 0 0 0 0 31 BHAVANI 1 0 0 0 0 0 0 0
32 NAVANEEDHAM 0 0 0 0 0 0 0 0 32 RAJAMMAL 0 0 0 0 0 0 0 1
33 BALAMMAL 1 0 1 0 0 0 1 0 33 SULOCHANA 0 0 0 0 0 0 0 0
34 SANJEEVAMMAL 0 0 1 0 0 0 1 0 34 ELLAMMAL 0 0 0 0 0 0 0 0
35 NAZEEMA 1 0 0 1 0 0 0 0 35 RANI 1 0 0 0 0 0 0 0
Age < 45 Yrs > 45 yrs
Sex
Diabetes Mellitus/Hyper-
tension/Smoking/
Alcohol Negative
IgG > 10 GPL < 10 GPL
IgM > 7 MPL < 7 MPL
Positive
1 0
FemaleMale
